Definition

An orally bioavailable selective estrogen receptor degrader/downregulator (SERD) and a structural analog of fulvestrant, with potential antineoplastic activity. Upon oral administration, SERD ZB-716 specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.